CoChat

Effects of non‐steroidal anti‐inflammatory drug treatments on cognitive decline vary by phase of pre‐clinical Alzheimer disease: findings from the randomized controlled Alzheimer's Disease Anti‐inflammatory Prevention Trial

Open access
Leoutsakos, Jeannie‐Marie S., Muthen, Bengt O., Breitner, John C.S., Lyketsos, Constantine G. · 2012 · International Journal of Geriatric Psychiatry
Cited by 104

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Objective: We examined the effects of non‐steroidal anti‐inflammatory drugs on cognitive decline as a function of phase of pre‐clinical Alzheimer disease. Methods: Given recent findings that cognitive decline accelerates as clinical diagnosis is approached, we used rate of decline as a proxy for phase of pre‐clinical Alzheimer disease. We fit growth mixture models of Modified Mini‐Mental State (3MS) Examination trajectories with data from 2388 participants in the Alzheimer's Disease Anti‐inflammatory Prevention Trial and included class‐specific effects of naproxen and celecoxib. Results: We identified three classes: “no decline”, “slow decline”, and “fast decline”, and examined the effects of celecoxib and naproxen on linear slope and rate of change by class. Inclusion of quadratic terms improved fit of the model (−2 log likelihood difference: 369.23;p < 0.001) but resulted in reversal of effects over time. Over 4 years, participants in the slow‐decline class on placebo typically lost 6.6 3MS points, whereas those on naproxen lost 3.1 points (p‐value for difference: 0.19). Participants in the fast‐decline class on placebo typically lost 11.2 points, but those on celecoxib first declined and then gained points (p‐value for difference from placebo: 0.04), whereas those on naproxen showed a typical decline of 24.9 points (p‐value for difference from placebo: <0.0001). Conclusions: Our results appeared statistically robust but provided some unexpected contrasts in effects of different treatments at different times. Naproxen may attenuate cognitive decline in slow decliners while accelerating decline in fast decliners. Celecoxib appeared to have similar effects at first but then attenuated change in fast decliners. Copyright © 2011 John Wiley & Sons, Ltd.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/gps.2723

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

Metadata

Authors
Leoutsakos, J. S., Muthen, B. O., Breitner, J. C. S., & Lyketsos, C. G.
Venue
International Journal of Geriatric Psychiatry
Publisher
Wiley
Published
2011-05-10
Volume
27
Issue
4
Pages
364-374
ISSN
  • 0885-6230 (ISSN-L)
  • 1099-1166
OpenAlex
W2117901796
Cited by
104
References
20
FWCI
6.89
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.